Safety and Tolerability of Sotagliflozin Among Kidney Transplant Recipients
Among stable KTRs, sotagliflozin caused an initial decline in eGFR of similar magnitude to patients with chronic kidney disease, with reversibility upon withdrawal. Access to follow-up eGFR measurements did not affect study adherence.
Authors
- Karela Herrera‐Enriquez
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Finnian R. Mc Causland (ORCID: https://orcid.org/0000-0002-0299-0533)
- Andrew S. Levey (ORCID: https://orcid.org/0000-0003-1491-501X)
- Martina M. McGrath (ORCID: https://orcid.org/0000-0001-6210-9341)
- Marc A. Pfeffer
Institutions
- Brigham and Women's Hospital (US)
- Tufts Medical Center (US)
Publication Details
- Journal
- Transplantation
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1097/tp.0000000000005503
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00